Amplification of immunological functions by subcutaneous injection of intermediate-high dose interleukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma

Transplantation

Volumn 70, Issue 7, 2000, Pages 1100-1104

  Toren, Amos ^a,b   Nagler, Arnon ^c   Rozenfeld Granot, Galit ^a,b   Levanon, Michal ^a,b   Davidson, Jacqueline ^a,b   Bielorai, Bella ^a,b   Kaplinsky, Chaim ^a,b   Meitar, Dafna ^a,b   Mandel, Mathilda ^a,b   Ackerstein, Aliza ^c   Ballin, Ami ^d   Attias, Dina ^e   Biniaminov, Miriam ^a,b   Rosenthal, Esther ^a,b   Brok Simoni, Frida ^a,b   Rechavi, Gideon ^a,b   Kaufmann, Yael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Edith Wolfson Hospital   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD3 ANTIGEN; CD56 ANTIGEN; ETOPOSIDE; INTERLEUKIN 2; MELPHALAN; PHYTOHEMAGGLUTININ; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ADULT; ARTICLE; AUTOTRANSPLANTATION; BRAIN DISEASE; CANCER CELL; CELL KILLING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEVER; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOTHERAPY; MALE; MONONUCLEAR CELL; NEUROBLASTOMA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0034668028     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200010150-00019     Document Type: Article

References (10)

1. High dose chemotherapy with autologous BM rescue in advanced stage IV neuroblastoma
2. A phase I clinical trial of recombinant interleukin-2 following high-dose chemoradiotherapy for hematological malignancy: Applicability to the elimination of minimal residual disease
3. Rapid reappearance of large granular lymphocytes (LGL) with recombinant reconstitution of NK activity after human bone marrow transplantation (BMT)
4. Interleukin-2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated killer (LAK) cytotoxicity
5. Role of interleukin-2 in human hematological malignancies
6. Immunotherapy with Interleukin-2 and recombinant interferon-alfa in lymphoma patients post autologous marrow or stem cell transplantation
7. High-dose systemic Interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study
8. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation
9. Phase I-II study of interleukin-2 after high-dose chemotherapy and autologous bone marrow transplantation in poorly responding neuroblastoma
10. Immunotherapy with low-dose recombinant IL-2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma